ARTICLE | Strategy
A CATT in the hat tale
CATT bolsters what is already known: Use of Avastin in AMD is all about money
May 2, 2011 7:00 AM UTC
A close analysis of data released last week from the Comparison of Age-Related Macular Degeneration Treatments Trials showed two things: Avastin bevacizumab was statistically non-inferior to Lucentis ranibuzimab and Lucentis was numerically somewhat better than Avastin on most safety and efficacy measures.
Beyond the data, conversations with physicians and a comparison of U.S. and European market share all indicate what was already known: decisions about whether patients receive Lucentis or Avastin for AMD are based entirely on money, not science or medicine...